Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 96-104, September 2010

Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians

  • Cynthia L. Arfken, Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA. Tel.: +1 313 993 3490; fax: +1 313 577 5062.
  • ,
  • Chris-Ellyn Johanson, Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA
    • CRS Associates, LLC, Chicago, IL 60616, USA
  • ,
  • Salvatore di Menza, M.S.

      Affiliations

    • CRS Associates, LLC, Chicago, IL 60616, USA
  • ,
  • Charles Roberts Schuster, Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA
    • CRS Associates, LLC, Chicago, IL 60616, USA

Received 13 January 2010; received in revised form 19 April 2010; accepted 5 May 2010. published online 05 July 2010.

Abstract 

Office-based treatment of opioid dependence with buprenorphine has the potential to expand treatment capacity in the United States. However, nationally, little is known about the number, characteristics, and experiences of physicians certified to prescribe buprenorphine. Moreover, little is known about the impact of easing federal regulations on the number of patients a physician is allowed to treat concurrently. To address these questions, surveys of national samples of physicians certified to prescribe buprenorphine (2004–2008) were analyzed (N = 6,892). There has been a continual increase in the number of physicians certified to prescribe buprenorphine, increase in the mean number of patients treated by physicians, and decrease in patients turned away, coinciding temporally with easing of federal regulations. In addition, most physicians prescribed buprenorphine outside of traditional treatment settings. The U.S. experiment in expanding Schedule III-V medications for opioid dependence to physicians outside of formal substance abuse treatment facilities appears to have resulted in expanded capacity.

Keywords: Buprenorphine, Suboxone, Subutex, Physicians, Survey

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0740-5472(10)00098-X

doi:10.1016/j.jsat.2010.05.004

Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 96-104, September 2010